<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Preeclampsia – MFM Clinical Update</title>
<style>
  body {
    margin: 0;
    background: #0f172a;
    color: #e5e7eb;
    font-family: system-ui, -apple-system, BlinkMacSystemFont, sans-serif;
    overflow: hidden;
  }
  .deck {
    display: flex;
    width: 1800vw;
    height: 100vh;
    transition: transform 0.6s ease;
  }
  .slide {
    width: 100vw;
    padding: 60px 80px;
    box-sizing: border-box;
    display: flex;
    flex-direction: column;
    justify-content: center;
  }
  h1 {
    font-size: 3.5rem;
    margin-bottom: 1rem;
    color: #60a5fa;
  }
  h2 {
    font-size: 2.5rem;
    margin-bottom: 1.5rem;
    color: #60a5fa;
  }
  h3 {
    font-size: 1.8rem;
    margin-top: 1.5rem;
    margin-bottom: 0.8rem;
    color: #93c5fd;
  }
  p, li {
    font-size: 1.5rem;
    line-height: 1.6;
    margin-bottom: 0.8rem;
  }
  ul {
    margin-left: 0;
    padding-left: 1.5rem;
  }
  li {
    margin-bottom: 1rem;
  }
  .highlight {
    color: #fbbf24;
    font-weight: 600;
  }
  .sub {
    font-size: 1.3rem;
    color: #cbd5e1;
    margin-left: 2rem;
  }
  .note {
    font-size: 1.2rem;
    color: #94a3b8;
    font-style: italic;
    margin-top: 1rem;
  }
  table {
    font-size: 1.4rem;
    border-collapse: collapse;
    width: 100%;
    margin-top: 1rem;
  }
  th, td {
    padding: 0.8rem;
    text-align: left;
    border-bottom: 1px solid #334155;
  }
  th {
    color: #60a5fa;
    font-weight: 600;
  }
  .controls {
    position: fixed;
    bottom: 20px;
    right: 20px;
    font-size: 1rem;
    color: #64748b;
  }
</style>
</head>
<body>
<div class="deck" id="deck">
  
  <!-- Slide 1 -->
  <section class="slide">
    <h1>Preeclampsia</h1>
    <p style="font-size: 2rem;">Early Identification & Evidence-Based Management</p>
    <p class="note">MFM Clinical Update 2025</p>
  </section>

  <!-- Slide 2 -->
  <section class="slide">
    <h2>Epidemiology & Impact</h2>
    <ul>
      <li><span class="highlight">2–8%</span> of pregnancies in the United States</li>
      <li>Leading cause of maternal morbidity and mortality worldwide</li>
      <li><span class="highlight">Disproportionate burden:</span> Black women 60% higher risk</li>
      <li>Associated with preterm birth, IUGR, placental abruption</li>
      <li>Long-term cardiovascular risk for mother and offspring</li>
    </ul>
    <p class="note">ACOG Practice Bulletin #222, 2020</p>
  </section>

  <!-- Slide 3 -->
  <section class="slide">
    <h2>Pathophysiology</h2>
    <ul>
      <li><span class="highlight">Stage 1 (Early pregnancy):</span> Abnormal placentation
        <div class="sub">• Inadequate trophoblast invasion</div>
        <div class="sub">• Failure of spiral artery remodeling</div>
      </li>
      <li><span class="highlight">Stage 2 (Mid-late pregnancy):</span> Maternal syndrome
        <div class="sub">• Endothelial dysfunction (↓ VEGF, ↑ sFlt-1, ↑ sEng)</div>
        <div class="sub">• Systemic inflammation and oxidative stress</div>
        <div class="sub">• Hypertension and end-organ damage</div>
      </li>
    </ul>
    <p class="note">sFlt-1/PlGF ratio increasingly used for diagnosis and prediction</p>
  </section>

  <!-- Slide 4 -->
  <section class="slide">
    <h2>Diagnostic Criteria (ACOG 2019)</h2>
    <h3>Blood Pressure</h3>
    <p>SBP ≥140 or DBP ≥90 mmHg on two occasions at least 4 hours apart <span class="highlight">after 20 weeks</span> in previously normotensive woman</p>
    
    <h3>Plus ONE of:</h3>
    <ul>
      <li>Proteinuria ≥300 mg/24h or protein/creatinine ≥0.3</li>
      <li>Thrombocytopenia (platelets <100,000)</li>
      <li>Renal insufficiency (Cr >1.1 or doubling of baseline)</li>
      <li>Elevated liver enzymes (2× upper limit)</li>
      <li>Pulmonary edema</li>
      <li>New-onset headache or visual symptoms</li>
    </ul>
  </section>

  <!-- Slide 5 -->
  <section class="slide">
    <h2>Preeclampsia with Severe Features</h2>
    <ul>
      <li><span class="highlight">Severe hypertension:</span> SBP ≥160 or DBP ≥110 mmHg</li>
      <li><span class="highlight">Thrombocytopenia:</span> Platelets <100,000/μL</li>
      <li><span class="highlight">Liver dysfunction:</span> Transaminases 2× normal, RUQ pain</li>
      <li><span class="highlight">Renal dysfunction:</span> Creatinine >1.1 mg/dL or doubling</li>
      <li><span class="highlight">Pulmonary edema</span></li>
      <li><span class="highlight">Cerebral or visual symptoms:</span> Persistent headache, scotomata</li>
    </ul>
    <p class="note">Severe features warrant closer monitoring and earlier delivery</p>
  </section>

  <!-- Slide 6 -->
  <section class="slide">
    <h2>Risk Stratification</h2>
    
    <h3>High-Risk Factors (>8% risk)</h3>
    <ul>
      <li>Prior preeclampsia (especially <34 weeks)</li>
      <li>Multifetal gestation</li>
      <li>Chronic hypertension</li>
      <li>Type 1 or 2 diabetes</li>
      <li>Renal disease</li>
      <li>Autoimmune disease (SLE, APS)</li>
    </ul>
    
    <h3>Moderate-Risk Factors</h3>
    <p class="sub">Nulliparity, obesity (BMI >30), family history, age ≥35, prior adverse pregnancy outcome, IVF, low socioeconomic status</p>
  </section>

  <!-- Slide 7 -->
  <section class="slide">
    <h2>First-Trimester Screening</h2>
    
    <h3>FMF Algorithm (11-13+6 weeks)</h3>
    <ul>
      <li>Maternal characteristics + history</li>
      <li>Mean arterial pressure (MAP)</li>
      <li>Uterine artery Doppler (pulsatility index)</li>
      <li>Serum PAPP-A and PlGF</li>
    </ul>
    <p><span class="highlight">Detection rate:</span> ~75% for early preeclampsia (<37 weeks) with 10% false positive rate</p>
    <p class="note">ASPRE trial demonstrated effectiveness of this approach</p>
  </section>

  <!-- Slide 8 -->
  <section class="slide">
    <h2>Aspirin Prophylaxis</h2>
    
    <h3>USPSTF & ACOG Recommendations (2021)</h3>
    <ul>
      <li><span class="highlight">Dose:</span> 81-162 mg daily (consider 162 mg for high-risk)</li>
      <li><span class="highlight">Timing:</span> Initiate <span class="highlight">before 16 weeks</span> (ideally 12 weeks)</li>
      <li><span class="highlight">Continue until delivery</span></li>
      <li><span class="highlight">Indication:</span> ≥1 high-risk factor OR ≥2 moderate-risk factors</li>
    </ul>
    
    <p style="margin-top: 1.5rem;"><span class="highlight">NNT:</span> 72 to prevent one case of preeclampsia</p>
    <p class="note">ASPRE trial: 62% reduction in early preeclampsia with 150mg at bedtime</p>
  </section>

  <!-- Slide 9 -->
  <section class="slide">
    <h2>Antenatal Surveillance</h2>
    
    <h3>Preeclampsia Without Severe Features</h3>
    <ul>
      <li>BP monitoring 2× weekly (can be outpatient)</li>
      <li>Weekly labs (CBC, LFTs, creatinine)</li>
      <li>Fetal testing: NST/BPP 1-2× weekly starting at diagnosis</li>
      <li>Growth ultrasound every 3 weeks</li>
    </ul>
    
    <h3>Preeclampsia With Severe Features</h3>
    <ul>
      <li>Inpatient management at ≥34 weeks</li>
      <li>Consider expectant management 23-33+6 weeks at tertiary center</li>
      <li>Daily labs, continuous or frequent BP monitoring</li>
      <li>Daily fetal testing</li>
    </ul>
  </section>

  <!-- Slide 10 -->
  <section class="slide">
    <h2>Acute Severe Hypertension Management</h2>
    
    <p><span class="highlight">Goal:</span> SBP 140-150 mmHg, DBP 90-100 mmHg within 30-60 minutes</p>
    
    <h3>First-Line Agents</h3>
    <table>
      <tr>
        <th>Medication</th>
        <th>Dose</th>
        <th>Notes</th>
      </tr>
      <tr>
        <td>Labetalol IV</td>
        <td>20 mg → 40 mg → 80 mg q10min</td>
        <td>Max 220 mg total</td>
      </tr>
      <tr>
        <td>Hydralazine IV</td>
        <td>5-10 mg q20min</td>
        <td>Max 20 mg total</td>
      </tr>
      <tr>
        <td>Nifedipine PO</td>
        <td>10-20 mg q20min</td>
        <td>Immediate release</td>
      </tr>
    </table>
    
    <p class="note">ACOG recommends treating sustained SBP ≥160 or DBP ≥110 mmHg</p>
  </section>

  <!-- Slide 11 -->
  <section class="slide">
    <h2>Magnesium Sulfate for Seizure Prophylaxis</h2>
    
    <h3>Indications</h3>
    <ul>
      <li>Preeclampsia with severe features</li>
      <li>During labor and 24-48 hours postpartum</li>
      <li>Treatment and prevention of eclamptic seizures</li>
    </ul>
    
    <h3>Dosing</h3>
    <p><span class="highlight">Loading:</span> 4-6 g IV over 15-20 minutes</p>
    <p><span class="highlight">Maintenance:</span> 2 g/hour continuous infusion</p>
    
    <h3>Monitoring</h3>
    <p class="sub">• Deep tendon reflexes (discontinue if absent)<br>
    • Respiratory rate >12/min<br>
    • Urine output >25 mL/hour<br>
    • Serum magnesium levels if renal insufficiency (goal 4-7 mEq/L)</p>
  </section>

  <!-- Slide 12 -->
  <section class="slide">
    <h2>Timing of Delivery</h2>
    
    <table>
      <tr>
        <th>Clinical Scenario</th>
        <th>Timing</th>
      </tr>
      <tr>
        <td>Preeclampsia without severe features</td>
        <td>37 0/7 weeks</td>
      </tr>
      <tr>
        <td>Preeclampsia with severe features</td>
        <td>34 0/7 weeks</td>
      </tr>
      <tr>
        <td>HELLP syndrome</td>
        <td>34 0/7 weeks</td>
      </tr>
      <tr>
        <td>Eclampsia</td>
        <td>Deliver after stabilization</td>
      </tr>
      <tr>
        <td>Severe features + maternal instability</td>
        <td>Immediate delivery</td>
      </tr>
    </table>
    
    <p class="note" style="margin-top: 1.5rem;">Betamethasone recommended <34 weeks; consider up to 36+6 weeks</p>
  </section>

  <!-- Slide 13 -->
  <section class="slide">
    <h2>HELLP Syndrome</h2>
    
    <h3>Diagnostic Criteria</h3>
    <ul>
      <li><span class="highlight">H</span>emolysis (↑ LDH, ↑ bilirubin, ↓ haptoglobin, schistocytes)</li>
      <li><span class="highlight">E</span>levated <span class="highlight">L</span>iver enzymes (AST/ALT >2× normal)</li>
      <li><span class="highlight">L</span>ow <span class="highlight">P</span>latelets (<100,000/μL)</li>
    </ul>
    
    <h3>Management</h3>
    <ul>
      <li>10-20% may present without hypertension or proteinuria</li>
      <li>Delivery indicated at ≥34 weeks</li>
      <li>Consider dexamethasone if <34 weeks and expectant management attempted</li>
      <li>Monitor for DIC, liver hematoma/rupture, acute renal failure</li>
    </ul>
  </section>

  <!-- Slide 14 -->
  <section class="slide">
    <h2>Postpartum Management</h2>
    
    <h3>Immediate Postpartum (0-72 hours)</h3>
    <ul>
      <li>Continue magnesium sulfate 24-48 hours</li>
      <li>Monitor BP closely (peaks 3-6 days postpartum)</li>
      <li>Treat severe hypertension aggressively</li>
      <li>Monitor for postpartum preeclampsia/eclampsia</li>
    </ul>
    
    <h3>Preferred Antihypertensives</h3>
    <p class="sub">• Labetalol, nifedipine (safe for breastfeeding)<br>
    • Avoid methyldopa (slow onset), ACE-I/ARBs (use with caution in breastfeeding)</p>
    
    <h3>NSAIDs</h3>
    <p class="sub">Use with caution; may worsen hypertension and renal function</p>
  </section>

  <!-- Slide 15 -->
  <section class="slide">
    <h2>Long-Term Cardiovascular Risk</h2>
    
    <ul>
      <li><span class="highlight">2-4× increased risk</span> of cardiovascular disease</li>
      <li><span class="highlight">2× increased risk</span> of stroke</li>
      <li>Risk of chronic hypertension, metabolic syndrome, diabetes</li>
      <li>Earlier age of cardiovascular events (40s-50s)</li>
    </ul>
    
    <h3>Postpartum Counseling</h3>
    <ul>
      <li>Discuss long-term cardiovascular risk</li>
      <li>Recommend BP check at 7-10 days, 6 weeks, and annually</li>
      <li>Lifestyle modifications: diet, exercise, weight management</li>
      <li>Consider cardiology referral for early preeclampsia or recurrent disease</li>
    </ul>
    
    <p class="note">AHA 2021: Preeclampsia is independent CV risk factor</p>
  </section>

  <!-- Slide 16 -->
  <section class="slide">
    <h2>Recurrence Risk & Future Pregnancy</h2>
    
    <table>
      <tr>
        <th>Prior Outcome</th>
        <th>Recurrence Risk</th>
      </tr>
      <tr>
        <td>Preeclampsia at term</td>
        <td>5-7%</td>
      </tr>
      <tr>
        <td>Preeclampsia <34 weeks</td>
        <td>25-65%</td>
      </tr>
      <tr>
        <td>Preeclampsia in 2 pregnancies</td>
        <td>32%</td>
      </tr>
      <tr>
        <td>Severe preeclampsia</td>
        <td>Up to 40%</td>
      </tr>
    </table>
    
    <h3>Preconception Counseling</h3>
    <p class="sub">• Optimize chronic conditions<br>
    • Aspirin prophylaxis starting <16 weeks<br>
    • Consider first-trimester screening<br>
    • Enhanced surveillance in subsequent pregnancy</p>
  </section>

  <!-- Slide 17 -->
  <section class="slide">
    <h2>Clinical Pearls</h2>
    
    <ul>
      <li><span class="highlight">Diagnosis doesn't require proteinuria</span> – other end-organ findings sufficient</li>
      <li><span class="highlight">Headache + hyperreflexia</span> doesn't predict seizure; magnesium still indicated</li>
      <li><span class="highlight">BP can normalize</span> between readings; don't dismiss diagnosis</li>
      <li><span class="highlight">Platelets often first to fall</span> – trend labs serially</li>
      <li><span class="highlight">Postpartum hypertension</span> peaks days 3-6, not immediately after delivery</li>
      <li><span class="highlight">Delivery is curative for fetus</span>, but maternal disease may progress 48-72h</li>
    </ul>
  </section>

  <!-- Slide 18 -->
  <section class="slide">
    <h2>Summary & Clinical Action Items</h2>
    
    <ul>
      <li><span class="highlight">Screen early:</span> Risk stratify at first prenatal visit</li>
      <li><span class="highlight">Prevent when possible:</span> Aspirin <16 weeks for high-risk patients</li>
      <li><span class="highlight">Diagnose accurately:</span> New hypertension + end-organ involvement</li>
      <li><span class="highlight">Manage severe features:</span> Control BP, give MgSO4, deliver appropriately</li>
      <li><span class="highlight">Time delivery correctly:</span> Balance maternal/fetal risks</li>
      <li><span class="highlight">Follow long-term:</span> Counsel on cardiovascular risk, ensure ongoing care</li>
    </ul>
    
    <p class="note" style="margin-top: 2rem; font-size: 1.4rem;">Evidence-based care can significantly reduce maternal morbidity and improve outcomes</p>
  </section>

</div>

<div class="controls">
  Use ← → arrow keys to navigate | Slide <span id="current">1</span> of 18
</div>

<script>
let index = 0;
const totalSlides = 18;
const deck = document.getElementById("deck");
const currentDisplay = document.getElementById("current");

function updateSlide() {
  index = Math.max(0, Math.min(index, totalSlides - 1));
  deck.style.transform = `translateX(-${index * 100}vw)`;
  currentDisplay.textContent = index + 1;
}

document.addEventListener("keydown", e => {
  if (e.key === "ArrowRight") {
    index++;
    updateSlide();
  }
  if (e.key === "ArrowLeft") {
    index--;
    updateSlide();
  }
  if (e.key === "Home") {
    index = 0;
    updateSlide();
  }
  if (e.key === "End") {
    index = totalSlides - 1;
    updateSlide();
  }
});

// Update initial display
updateSlide();
</script>
</body>
</html>
